List of Figures
Figure 1-1: Characteristics of an Ideal Drug Delivery System
Figure 2-1: Limitations of the Conventional Drug Delivery Systems
Figure 2-2: Diversification of the Novel Drug Delivery Platforms
Figure 2-3: History of Drug Delivery Technology from First Generation till Third Generation
Figure 2-4: Barriers to be Overcome by the Third Generation Drug Delivery System
Figure 2-5: Demonstration of the Targeted & Non-Targeted Drug Delivery
Figure 2-6: Controlled Drug Release is by Zero Order Mechanism
Figure 3-1: Plasma Concentration v/s Time Profile in Conventional & Controlled Release
Figure 3-2: Comparison of Varied Modified Drug Release Systems
Figure 3-3: Illustration of Mechanism of Pulsatile Drug Release in Pulsincap
Figure 3-4: Classification Based Over the Technicality Erudition
Figure 3-5: Structural Differentiation among Varied Classified Drug Delivery Systems
Figure 3-6: Classification Based over the Route of Administration
Figure 4-1: Differentiation of the Two Forms of the Diffusion Controlled Mechanisms
Figure 4-2: Mechanism of Encapsulation Dissolution Controlled System
Figure 4-3: Osmotic Release of the Drug Delivery with the Controlled Mechanism
Figure 4-4: Illustration of Erosion Mechanisms Found in Matrix Systems
Figure 5-1: Categorization of Polymeric Controlled Drug Delivery Devices
Figure 5-2: Varied Nanostructures Available for the Nanoparticulate Delivery System
Figure 6-1: Global - Controlled Release Drug Clinical Pipeline by Phase (%), 2020 till 2026
Figure 6-2: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2020 till 2026
Figure 6-3: Global - Controlled Release Drug Clinical Pipeline by Country/Region (Number), 2020 till 2026
Figure 6-4: Global - Controlled Release Clinical Drug Pipeline by Mode of Action (Number), 2020 till 2026
Figure 6-5: Global - Controlled Release Drug Clinical Pipeline by Drug Class (Number), 2020 till 2026
Figure 6-6: Global - Controlled Release Drug Clinical Pipeline by indication (Number), 2020 till 2026
Figure 7-1: Major Non-Invasive Administrative Routes of Insulin Delivery
Figure 7-2: Layout of the Controlled Drug Delivery Approaches in Cancer Therapeutics
Figure 7-3: Controlled Drug Delivery Approaches used to Deliver Drugs to CNS
Figure 8-1: Dosage Formulations for the Controlled Drug Delivery
Figure 8-2: Mechanism of the Controlled Drug Release of the Solid Dosage Forms
Figure 8-3: Representation of Categories of Liquid Dosage Form
Figure 8-4: Mechanism of Controlled Delivery of Parenteral Dosage Forms
Figure 8-5: General Forms of Oral Controlled Release System Mechanism
Figure 8-6: Schematic Diffusion Controlled Drug Release from Inert Matrices
Figure 8-7: Demonstration of the Osmotic Pump Drug Release Mechanism
Figure 9-1: Namzaric – Price of Oral Capsule, Extended Release of Dosage 10 mg-7 mg (US$), March’ 2020
Figure 9-2: Namzaric – Price of Oral Capsule, Extended Release of Dosage 10 mg-14 mg (US$), March’ 2020
Figure 9-3: Namzaric – Price of Oral Capsule, Extended Release of Dosage 10 mg-21 mg (US$), March’ 2020
Figure 9-4: Namzaric – Price of Oral Capsule, Extended Release of Dosage 10 mg-28 mg (US$), March’ 2020
Figure 9-5: Namenda XR – Available Dosage Strengths (mg), March’ 2020
Figure 9-6: Namenda XR – Price of Oral Capsules, Extended Release 7 mg (US$), March'2020
Figure 9-7: Namenda XR – Price of Oral Capsules, Extended Release 14 mg (US$), March'2020
Figure 9-8: Namenda XR – Price of Oral Capsules, Extended Release 21 mg (US$), March'2020
Figure 9-9: Namenda XR – Price of Oral Capsules, Extended Release 28 mg (US$), March'2020
Figure 9-10: Global - Namenda XR Quarterly Sales Q1 – Q4 (US$ Million), 2017 & 2018
Figure 9-11: Razadyne ER – Available Dosage Strengths (mg), March’ 2020
Figure 9-12: Razadyne ER – Price of Oral Capsules, Extended Release 8 mg (US$), March’ 2020
Figure 9-13: Razadyne ER – Price of Oral Capsules, Extended Release 16 mg (US$), March’ 2020
Figure 9-14: Razadyne ER – Price of Oral Capsules, Extended Release 24 mg (US$), March’ 2020
Figure 10-1: Gocovri – Avaialable Dosage Strengths (mg)
Figure 10-2: Gocovri – Price of Oral Capsule, Extended Release of Dosage 68.5 mg (US$), March’ 2020
Figure 10-3: Gocovri – Price of Oral Capsule, Extended Release of Dosage 137 mg (US$), March’ 2020
Figure 10-4: Global - Gocovri Quarterly Sales Q1 – Q4 (US$ Million), 2019
Figure 10-5: Global - Gocovri Annual Sales (US$ Million), 2018 & 2019
Figure 10-6: Osmolex ER – Available Dosage Strengths (mg), March’ 2020
Figure 10-7: Osmolex ER – Price of Oral Capsules, Extended Release 129 mg (US$), March’ 2020
Figure 10-8: Osmolex ER – Price of Oral Capsules, Extended Release 193 mg (US$), March’ 2020
Figure 10-9: Osmolex ER – Price of Oral Tablets, Extended Release 258 mg (US$), March’ 2020
Figure 10-10: Global - Selling, General & & Administrative Expenses Q1 – Q4 (US$ Million), 2018
Figure 10-11: Global - Selling, General & & Administrative Expenses Q1 – Q4 (US$ Million), 2019
Figure 10-12: Global - Osmolex ER Selling, General & Administrative Expenses Q1 (US$ Million), 2018 & 2019
Figure 10-13: Global - Osmolex ER Selling, General & Administrative Expenses Q2 (US$ Million), 2018 & 2019
Figure 10-14: Global - Osmolex ER Selling, General & Administrative Expenses Q3 (US$ Million), 2018 & 2019
Figure 10-15: Global - Osmolex ER Q4 Selling, General & Administrative Expenses (US$ Million), 2018 & 2019
Figure 11-1: Perseris: Available Dosage Strengths (mg)
Figure 11-2: Perseris: Price of 1 Subcutaneous Powder for Injection, Extended Release (US$) March’ 2020
Figure 11-3: Global - Perseris Estimated Annual Sales (US$ Million), 2019 - 2025
Figure 11-4: Invega – Available Dosage Strengths (mg)
Figure 11-5: Invega – Price of Oral Tablets, Extended Release of Dosage 1.5 mg (US$), March’ 2020
Figure 11-6: Invega – Price of Oral Tablets, Extended Release of Dosage 3 mg (US$), March’ 2020
Figure 11-7: Invega – Price of Oral Tablets, Extended Release of Dosage 6 mg (US$), March’ 2020
Figure 11-8: Invega – Price of Oral Tablets, Extended Release of Dosage 9 mg (US$), March’ 2020
Figure 11-9: Invega Sustenna – Available Dosage Strengths (mg)
Figure 11-10: Invega Trinza – Available Dosage Strengths (mg)
Figure 11-11: Invega Sustenna – Price of Intramuscular Suspension, Extended Release of Dosage 39 mg (US$), March’ 2020
Figure 11-12: Invega Sustenna – Price of Intramuscular Suspension, Extended Release of Dosage 78 mg (US$), March’ 2020
Figure 11-13: Invega Sustenna – Price of Intramuscular Suspension, Extended Release of Dosage 117 mg (US$), March’ 2020
Figure 11-14: Invega Sustenna – Price of Intramuscular Suspension, Extended Release of Dosage 156 mg (US$), March’ 2020
Figure 11-15: Invega Sustenna – Price of Intramuscular Suspension, Extended Release of Dosage 234 mg (US$), March’ 2020
Figure 11-16: Invega Trinza – Price of Intramuscular Suspension Extended Release 273 mg (US$), March’ 2020
Figure 11-17: Invega Trinza – Price of Intramuscular Suspension Extended Release 410 mg (US$), March’ 2020
Figure 11-18: Invega Trinza – Price of Intramuscular Suspension Extended Release 546 mg (US$), March’ 2020
Figure 11-19: Invega Trinza – Price of Intramuscular Suspension Extended Release 819 mg (US$), March’ 2020
Figure 11-20: US - Invega Sustenna/ Invega Trinza Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 11-21: Global - Invega Sustenna/ Invega Trinza Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 11-22: Global – Invega Sustenna/ Invega Trinza Regional Sales Q1 – Q4 (US$ Million), 2018
Figure 11-23: US – Invega Sustenna/ Invega Trinza Regional Sales Q1 – Q4 (US$ Million), 2019
Figure 11-24: Global – Invega Sustenna/ Invega Trinza Sales Q1 – Q4 (US$ Million), 2019
Figure 11-25: Global – Invega Sustenna/ Invega Trinza Regional Sales Q1 – Q4 (US$ Million), 2019
Figure 11-26: Seroquel XR – Available Dosage Strengths (mg)
Figure 11-27: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage 50 mg (US$), March’ 2020
Figure 11-28: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage 150 mg (US$), March’ 2020
Figure 11-29: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage 200 mg (US$), March’ 2020
Figure 11-30: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage 300 mg (US$), March’ 2020
Figure 11-31: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage 300 mg (US$), March’ 2020
Figure 11-32: Global - Seroquel XR Total Annual Sales (US$ Million), 2017 - 2019
Figure 11-33: Global - Seroquel XR Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 11-34: Global - Seroquel XR Quarterly Sales Q1 – Q4 (US$ Million), 2019
Figure 11-35: Abilify Maintena – Available Dosage Strengths (mg)
Figure 11-36: Abilify Maintena – Price of Intramuscular Powder for Injection, Extended Release for Dosage 300 mg & 400 mg (US$), March’ 2020
Figure 11-37: Global - Abilify Maintena Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 11-38: Global - Abilify Maintena Quarterly Sales Q1 – Q3 (US$ Million), 2019
Figure 11-39: North America - Abilify Maintena Quarterly Sales Q1 – Q4 (US$ Million), 2018 & 2019
Figure 11-40: Aristada – Available Dosage Strengths (mg)
Figure 11-41: Aristada – Price of Intramuscular Suspension, Extended Release of Dosage 441 mg (US$), March’ 2020
Figure 11-42: Aristada – Price of Intramuscular Suspension, Extended Release of Dosage 662 mg (US$), March’ 2020
Figure 11-43: Aristada – Price of Intramuscular Suspension, Extended Release of Dosage 882 mg (US$), March’ 2020
Figure 11-44: Aristada – Price of Intramuscular Suspension, Extended Release of Dosage 1064 mg (US$), March’ 2020
Figure 11-45: Global – Aristada Quarterly Sales Q1-Q4 (US$ Million), 2018
Figure 11-46: Global – Aristada Quarterly Sales Q1-Q4 (US$ Million), 2019
Figure 12-1: Zohydro ER – Available Dosage Strengths (mg)
Figure 12-2: Zohydro ER – Price of Oral Capsules, Extended Release of Dosage 10 mg (US$), 2020
Figure 12-3: Zohydro ER – Price of Oral Capsules, Extended Release of Dosage 15 mg (US$), 2020
Figure 12-4: Zohydro ER – Price of Oral Capsules, Extended Release of Dosage 20 mg (US$), 2020
Figure 12-5: Zohydro ER – Price of Oral Capsules, Extended Release of Dosage 30 mg (US$), 2020
Figure 12-6: Zohydro ER – Price of Oral Capsules, Extended Release of Dosage 40 mg (US$), 2020
Figure 12-7: Zohydro ER – Price of Oral Capsules, Extended Release of Dosage 50 mg (US$), 2020
Figure 12-8: Global – Zohydro ER Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 12-9: Hysingla ER – Available Dosage Strengths (mg)
Figure 12-10: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 20 mg (US$), 2020
Figure 12-11: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 30 mg (US$), 2020
Figure 12-12: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 40 mg (US$), 2020
Figure 12-13: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 60 mg (US$), 2020
Figure 12-14: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 80 mg (US$), 2020
Figure 12-15: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 100 mg (US$), 2020
Figure 12-16: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 120 mg (US$), 2020
Figure 12-17: Nucynta ER – Available Dosage Strengths (mg)
Figure 12-18: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 50 mg (US$), 2020
Figure 12-19: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 100 mg (US$), 2020
Figure 12-20: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 150 mg (US$), 2020
Figure 12-21: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 200 mg (US$), 2020
Figure 12-22: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 250 mg (US$), 2020
Figure 12-23: Global – Nucynta ER Annual Sales (US$ Million), 2018 & 2019
Figure 12-24: Global – Nucynta ER Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 12-25: Global – Nucynta ER Quarterly Sales Q1 – Q4 (US$ Million), 2019
Figure 12-26: Kadian – Available Dosage Strengths (mg)
Figure 12-27: Kadian – Price of Oral Capsules, Extended Release of Dosage 10 mg/12 to 24 hr (US$), 2020
Figure 12-28: Kadian – Price of Oral Capsules, Extended Release of Dosage 20 mg/12 to 24 hr (US$), 2020
Figure 12-29: Kadian – Price of Oral Capsules, Extended Release of Dosage 30 mg/12 to 24 hr (US$), 2020
Figure 12-30: Kadian – Price of Oral Capsules, Extended Release of Dosage 40 mg/12 to 24 hr (US$), 2020
Figure 12-31: Kadian – Price of Oral Capsules, Extended Release of Dosage 50 mg/12 to 24 hr (US$), 2020
Figure 12-32: Kadian – Price of Oral Capsules, Extended Release of Dosage 60 mg/12 to 24 hr (US$), 2020
Figure 12-33: Kadian – Price of Oral Capsules, Extended Release of Dosage 80 mg/12 to 24 hr (US$), 2020
Figure 12-34: Kadian – Price of Oral Capsules, Extended Release of Dosage 100 mg/12 to 24 hr (US$), 2020
Figure 12-35: Kadian – Price of Oral Capsules, Extended Release of Dosage 200 mg/12 to 24 hr (US$), 2020
Figure 12-36: Arymo ER – Available Dosage Strengths (mg)
Figure 12-37: Global - Price of Arymo ER Oral Tablets, Extended Release of Dosage 15 mg/8 to 12 hr (US$), 2020
Figure 12-38: Global - Price of Arymo ER Oral Tablets, Extended Release of Dosage 30 mg/8 to 12 hr (US$), 2020
Figure 12-39: Global - Price of Arymo ER Oral Tablets, Extended Release of Dosage 60 mg/8 to 12 hr (US$), 2020
Figure 12-40: Global – Arymo ER Quarterly Sales Q2 & Q3 (US$ Million), 2018
Figure 12-41: Xtampza ER – Available Dosage Strengths (mg)
Figure 12-42: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 9 mg (US$), 2020
Figure 12-43: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 13.5 mg (US$), 2020
Figure 12-44: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 18 mg (US$), 2020
Figure 12-45: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 27 mg (US$), 2020
Figure 12-46: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 36 mg (US$), 2020
Figure 12-47: Global – Xtampza ER Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 12-48: Global – Xtampza ER Quarterly Sales Q1 – Q4 (US$ Million), 2019
Figure 12-49: MS Contin – Available Dosage Strengths (mg)
Figure 12-50: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 15 mg/ 8 to 12 hr (US$), 2020
Figure 12-51: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 30 mg/ 8 to 12 hr (US$), 2020
Figure 12-52: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 60 mg/ 8 to 12 hr (US$), 2020
Figure 12-53: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 100 mg/ 8 to 12 hr (US$), 2020
Figure 12-54: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 200 mg/ 8 to 12 hr (US$), 2020
Figure 12-55: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 20 mg – 0.8 mg (US$), 2020
Figure 12-56: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 30 mg – 1.2mg (US$), 2020
Figure 12-57: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 50 mg – 2mg (US$), 2020
Figure 12-58: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 60 mg – 2.4 mg (US$), 2020
Figure 12-59: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 80 mg – 3.2mg (US$), 2020
Figure 12-60: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 100 mg – 4 mg (US$), 2020
Figure 13-1: Ampyra – Price of Oral Tablet, Extended Release of Dosage 10 mg (US$), 2020
Figure 13-2: Global – Ampyra Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 13-3: Global – Ampyra Quarterly Sales Q1 – Q4 (US$ Million), 2019
Figure 13-4: Global – Ampyra Total Sales (US$ Million), 2018 & 2019
Figure 13-5: Tecfidera – Available Dosage Strengths (mg)
Figure 13-6: Tecfidera - Price of Oral Capsule, Delayed Release of Dosage 120 mg (US$), 2020
Figure 13-7: Tecfidera - Price of Oral Capsule, Delayed Release of Dosage 240 mg (US$), 2020
Figure 13-8: Global – Tecdifera Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 13-9: Global – Tecdifera Quarterly Sales Q1 – Q3 (US$ Million), 2019
Figure 13-10: US - Tecdifera Quarterly Sales Q1 – Q3 (US$ Million), 2018 & 2019
Figure 13-11: Rayos – Available Dosage Strengths (mg)
Figure 13-12: Rayos - Price of Oral Tablet, Delayed Release of Dosage 1 mg (US$), 2020
Figure 13-13: Rayos - Price of Oral Tablet, Delayed Release of Dosage 2 mg (US$), 2020
Figure 13-14: Rayos - Price of Oral Tablet, Delayed Release of Dosage 5 mg (US$), 2020
Figure 13-15: Global - Rayos Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 13-16: Global - Rayos Quarterly Sales Q1 – Q4 (US$ Million 2019
Figure 13-17: Vumerity – Price of 231 mg Bottle, Delayed Release (US$), 2020
Figure 13-18: Global – Vumerity Fourth Quarter Sales Q4 (US$ Million), 2019
Figure 14-1: Glumetza – Available Dosage Strengths (mg)
Figure 14-2: Global – Price of Glumetza Oral Tablets, Extended Release of Dosage 500 mg (US$), 2020
Figure 14-3: Global – Price of Glumetza Oral Tablets, Extended Release of Dosage 1000 mg (US$), 2020
Figure 14-4: Glucotrol XL – Available Dosage Strengths (mg)
Figure 14-5: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 2.5 mg (US$), 2020
Figure 14-6: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 5 mg (US$), 2020
Figure 14-7: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 5 mg (US$), 2020
Figure 14-8: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 10 mg (US$), 2020
Figure 14-9: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 10 mg (US$), 2020
Figure 14-10: Fortamet – Available Dosage Strengths (mg)
Figure 14-11: Global – Price of Fortamet Oral Tablets, Extended Release of Dosage 500 mg (US$), 2020
Figure 14-12: Global – Price of Fortamet Oral Tablets, Extended Release of Dosage 1000 mg (US$), 2020
Figure 14-13: Glucophage XR – Available Dosage Strengths (mg)
Figure 14-14: Global – Price of Glucophage XR Oral Tablet, Extended Release of Dosage 500 mg (US$), 2020
Figure 14-15: Global – Price of Glucophage XR Oral Tablet, Extended Release of Dosage 750 mg (US$), 2020
Figure 14-16: Global – Price of Bydureon Powder for Injection of Dosage 2mg (US$), 2020
Figure 14-17: Global - Bydureon Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 14-18: Global - Bydureon Quarterly Sales Q1 – Q4 (US$ Million), 2019
Figure 15-1: Procardia XL – Available Dosage Strengths (mg)
Figure 15-2: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 30 mg (US$), 2020
Figure 15-3: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 30 mg (US$), 2020
Figure 15-4: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 60 mg (US$), 2020
Figure 15-5: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 60 mg (US$), 2020
Figure 15-6: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 90 mg (US$), 2020
Figure 15-7: Toprol XL – Available Dosage Strengths
Figure 15-8: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 25 mg (US$), 2020
Figure 15-9: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 25 mg (US$), 2020
Figure 15-10: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 50 mg (US$), 2020
Figure 15-11: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 50 mg (US$), 2020
Figure 15-12: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 100 mg (US$), 2020
Figure 15-13: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 100 mg (US$), 2020
Figure 15-14: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 200 mg (US$), 2020
Figure 15-15: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 200 mg (US$), 2020
Figure 15-16: Adalat CC – Available Dosage Strengths (mg)
Figure 15-17: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 30 mg (US$), 2020
Figure 15-18: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 30 mg (US$), 2020
Figure 15-19: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 60 mg (US$), 2020
Figure 15-20: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 60 mg (US$), 2020
Figure 15-21: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 90 mg (US$), 2020
Figure 15-22: Verelan PM – Available Dosage Strengths (mg)
Figure 15-23: Global – Price of Verelan PM Oral Capsule, Extended Release of Dosage 200 mg/24 hr (US$), 2020
Figure 15-24: Global – Price of Verelan PM Oral Capsule, Extended Release of Dosage 300 mg/24 hr (US$), 2020
Figure 15-25: Plendil – Available Dosage Strengths (mg)
Figure 15-26: Global – Price of Plendil Oral Tablet, Extended Release of Dosage 2.5 mg (US$), 2020
Figure 15-27: Global – Price of Plendil Oral Tablet, Extended Release of Dosage 5 mg (US$), 2020
Figure 15-28: Global – Price of Plendil Oral Tablet, Extended Release of Dosage 10 mg (US$), 2020
Figure 15-29: Cardizem LA – Available Dosage Strengths (mg)
Figure 15-30: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 120 mg/24 hr (US$), 2020
Figure 15-31: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 120 mg/24 hr (US$), 2020
Figure 15-32: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 180 mg/24 hr (US$), 2020
Figure 15-33: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 180 mg/24 hr (US$), 2020
Figure 15-34: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 240 mg/24 hr (US$), 2020
Figure 15-35: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 240 mg/24 hr (US$), 2020
Figure 15-36: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 300 mg/24 hr (US$), 2020
Figure 15-37: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 300 mg/24 hr (US$), 2020
Figure 15-38: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 360 mg/24 hr (US$), 2020
Figure 15-39: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 360 mg/24 hr (US$), 2020
Figure 15-40: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 420 mg/24 hr (US$), 2020
Figure 15-41: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 420 mg/24 hr (US$), 2020
Figure 18-1: US –Controlled Release Market Size (US$ Billion), 2019 - 2026
Figure 18-2: US – Population Above & Below 65 Years of Age (%), 2018
Figure 18-3: US – Share in Global Controlled Release Drug Market (%), 2019
Figure 18-4: Europe –Controlled Release Drug Delivery Market Size (US$ Billion), 2019 - 2026
Figure 18-5: Europe – Share in Global Controlled Release Drug Market (%), 2019
Figure 18-6: European Union – Population Above & Below 65 Years (%), 2018
Figure 18-7: European Union – Estimated Cases of Dementia, 2030 & 2050
Figure 18-8: Japan – Population Above & Below 65 Years (%), 2019
Figure 18-9: Japan – Dementia Cases (Million), 2018 & 2025
Figure 19-1: Accelerative Parameters of Controlled Drug Delivery Systems
Figure 19-2: Major Challenges Faced by Controlled Drug Delivery System
Figure 20-1: Global – Controlled Release Drug Delivery Market Size (US$ Billion), 2019 - 2026